DNase I与低分子量肝素在多微生物腹腔脓毒症小鼠模型中的作用
研究在盲肠结扎穿孔(CLP)所致多微生物腹腔脓毒症C57Bl/6小鼠中,比较生理盐水、DNase I(腹腔内20 mg/kg/8 h)、低分子量肝素(达肝素,皮下500 IU/kg/12 h)及两药联合对72 h生存的影响。DNase I组生存率81.8%、低分子量肝素组83.3%,均高于生理盐水组38.7%和联合组48.8%(P < 0.05);联合组较生理盐水组生存改善小且无统计学意义。单药可能通过降低血中细菌负荷、瓜氨酸化组蛋白-H3和凝血酶-抗凝血酶复合物、改善蛋白C水平而改善生存。作者认为腹腔内给予DNase I与低分子量肝素联用可能存在负性药物相互作用。
要点
- CLP脓毒症小鼠中,DNase I单药(腹腔内20 mg/kg/8 h)生存率81.8%,低分子量肝素单药(达肝素皮下500 IU/kg/12 h)83.3%,均高于生理盐水组38.7%(P < 0.05)。
- 两药联合组生存率48.8%,低于两个单药组(P < 0.05),较生理盐水组改善小且无统计学意义。
- 低分子量肝素组达到预防范围0.12 ± 0.07 IU/mL。
- 单药可能通过降低血中细菌负荷、瓜氨酸化组蛋白-H3和凝血酶-抗凝血酶复合物、改善蛋白C水平改善生存。
- 作者认为腹腔内给予DNase I与低分子量肝素联用在小鼠多微生物腹腔脓毒症模型中可能存在负性药物相互作用。
适用人群与场景
- C57Bl/6小鼠,8–12周龄,雌雄均有,接受盲肠结扎穿孔(CLP)或假手术。
- 所有小鼠均给予抗生素和液体。
处置流程与药物剂量
- DNase I:腹腔内注射,20 mg/kg/8 h。
- 低分子量肝素:达肝素,皮下注射500 IU/kg/12 h,达到预防范围0.12 ± 0.07 IU/mL。
- 联合组:同时给予上述DNase I与达肝素方案。
- 对照:生理盐水;所有小鼠均给予抗生素和液体,观察72 h生存。
研究设计与关键结果
- 研究类型:小鼠(C57Bl/6,8–12周龄,雌雄均有)多微生物腹腔脓毒症(CLP)模型,每组n = 12–31,观察72 h生存。
- 生存率:DNase I组81.8%、低分子量肝素组83.3%,均高于生理盐水组38.7%和联合组48.8%(P < 0.05)。
- 联合组较生理盐水组生存改善小且无统计学意义。
- 低分子量肝素组达到预防范围0.12 ± 0.07 IU/mL。
- 单药可能通过降低血中细菌负荷、瓜氨酸化组蛋白-H3和凝血酶-抗凝血酶复合物、改善蛋白C水平改善生存。
证据类型、等级与局限
- 证据类型:动物实验(小鼠CLP脓毒症模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在小鼠多微生物腹腔脓毒症模型中,腹腔内给予DNase I与低分子量肝素联用可能存在负性药物相互作用;该结论来自动物模型,不能直接外推至临床决策。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Introduction: Cell-free DNA (CFDNA) has emerged as a prognostic biomarker in patients with sepsis. Circulating CFDNA is hypothesized to be associated with histones in the form of nucleosomes. In vitro, DNA activates coagulation and inhibits fibrinolysis, whereas histones activate platelets and are cytotoxic to endothelial cells. Previous studies have targeted CFDNA or histones in animal models of sepsis using DNase I or heparins, respectively, which has reduced inflammatory and thrombosis markers, thereby improving survival. In this study, we explored the possibility that the combination of DNase I and a low-molecular weight heparin (LMWH) may be a better therapeutic approach than monotherapy in a murine model of abdominal sepsis. Methods: C57Bl/6 mice (8-12 weeks old, both sexes) were subjected to either cecal ligation and puncture or sham surgery. Mice were given antibiotics, fluids, and either saline, DNase I (intraperitoneally, 20 mg/kg/8 h), LMWH (dalteparin, subcutaneously 500 IU/kg/12 h), or a combination of both (n = 12-31). Mice were monitored over 72 h for survival. Organs and blood were harvested for analysis. Levels of LMWH, CFDNA, IL-6, citrullinated histone-H3, thrombin-antithrombin complexes, and protein C were measured in plasma. Results: Administration of either DNase I (81.8%) or LMWH (83.3%, prophylactic range of 0.12 ± 0.07 IU/mL achieved) improved the survival of septic mice compared with saline- (38.7%) and combination-treated mice (48.8%, P < 0.05). Combination-treated mice also showed a small but insignificant improvement in survival compared with saline-treated cecal ligation and puncture mice. Monotherapies may be improving survival by reducing blood bacterial loads, citrullinated histone-H3, and thrombin-antithrombin complexes, and improving protein C levels. Conclusions: Compared with saline- and combination-treated mice, administration of monotherapies to septic mice improved survival. These findings suggest that there may be a negative drug-drug interaction between DNase I and LMWH when DNase I is administered intraperitoneally in a murine model of polymicrobial abdominal sepsis.
参考来源
- Medeiros SK, Sharma N, Dwivedi D, et al. THE EFFECTS OF DNASE I AND LOW-MOLECULAR-WEIGHT HEPARIN IN A MURINE MODEL OF POLYMICROBIAL ABDOMINAL SEPSIS. Shock. 2023. PMID: 36852972. doi:10.1097/SHK.0000000000002095
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。